Therapeutic Immunization against Glioblastoma.

Int J Mol Sci · 2018 · PMC6163986 · PMID 30150597

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Six-month survival on the GLIOVAC regimen was 100%, and 12-month survival was 40%, providing initial evidence of low toxicity and promising activity of this new therapy with a highly significant overall survival (OS) increase [ 28 ], when compared to historic control patients.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.